| Entry |
|
|---|
| Name |
Dexmedetomidine (USAN/INN);
Dexdor (TN);
Precedex (TN) |
|---|
| Formula |
C13H16N2
|
|---|
| Exact mass |
200.1313
|
|---|
| Mol weight |
200.2795
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Cardiovascular agent
DG01456 Adrenergic receptor agonist
DG01450 alpha-Adrenergic receptor agonist
DG01449 alpha2-Adrenergic receptor agonist
Metabolizing enzyme substrate
DG01892 CYP1A2 substrate
DG01638 CYP2A6 substrate
DG01639 CYP2C19 substrate
DG01644 CYP2D6 substrate
DG02855 CYP2E1 substrate
|
|---|
| Remark |
| Product (DG00926): | D01205<JP/US> |
|
|---|
| Efficacy |
Sedative-hypnotic, Tranquilizer, alpha2-Adrenergic receptor agonist |
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
|
|---|
| Metabolism |
Enzyme: CYP2A6 [HSA: 1548]; CYP1A2 [HSA: 1544], CYP2E1 [HSA: 1571], CYP2D6 [HSA: 1565], CYP2C19 [HSA: 1557]
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07215 | alpha-Adrenergic receptor agonists/antagonists |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N05 PSYCHOLEPTICS
N05C HYPNOTICS AND SEDATIVES
N05CM Other hypnotics and sedatives
N05CM18 Dexmedetomidine
D00514 Dexmedetomidine (USAN/INN)
Drug groups [BR:br08330]
Cardiovascular agent
DG01456 Adrenergic receptor agonist
DG01450 alpha-Adrenergic receptor agonist
DG01449 alpha2-Adrenergic receptor agonist
DG00926 Dexmedetomidine
D00514 Dexmedetomidine
Metabolizing enzyme substrate
DG01892 CYP1A2 substrate
DG00926 Dexmedetomidine
D00514 Dexmedetomidine
DG01638 CYP2A6 substrate
DG00926 Dexmedetomidine
D00514 Dexmedetomidine
DG01639 CYP2C19 substrate
DG00926 Dexmedetomidine
D00514 Dexmedetomidine
DG01644 CYP2D6 substrate
DG00926 Dexmedetomidine
D00514 Dexmedetomidine
DG02855 CYP2E1 substrate
DG00926 Dexmedetomidine
D00514 Dexmedetomidine
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Adrenaline
ADRA2
D00514 Dexmedetomidine (USAN/INN)
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D00514
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D00514
Drug groups [BR:br08330]
Cardiovascular agent
DG01456 Adrenergic receptor agonist
DG01450 alpha-Adrenergic receptor agonist
DG01449 alpha2-Adrenergic receptor agonist
DG00926 Dexmedetomidine
Metabolizing enzyme substrate
DG01892 CYP1A2 substrate
DG00926 Dexmedetomidine
DG01638 CYP2A6 substrate
DG00926 Dexmedetomidine
DG01639 CYP2C19 substrate
DG00926 Dexmedetomidine
DG01644 CYP2D6 substrate
DG00926 Dexmedetomidine
DG02855 CYP2E1 substrate
DG00926 Dexmedetomidine
|
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 15
1 C8y C 21.8688 -21.7213
2 C1c C 23.0601 -20.9504
3 C8y C 20.6775 -20.9504
4 C8x C 21.8688 -23.0527
5 C8y C 24.3214 -21.7213
6 C1a C 23.0601 -19.5490
7 C8y C 19.4162 -21.7213
8 C1a C 20.6075 -19.5490
9 C8x C 20.6775 -23.7534
10 C8x C 24.3214 -23.1228
11 N5x N 25.5828 -21.2307
12 C8x C 19.4162 -23.1228
13 C1a C 18.2249 -21.0205
14 N4x N 25.6528 -23.4731
15 C8x C 26.4236 -22.3519
BOND 16
1 1 2 1
2 1 3 2
3 1 4 1
4 2 5 1
5 2 6 1 #Down
6 3 7 1
7 3 8 1
8 4 9 2
9 5 10 2
10 5 11 1
11 7 12 2
12 7 13 1
13 10 14 1
14 11 15 2
15 9 12 1
16 14 15 1
|
|---|
